Biocytogen Pharmaceuticals (Beijing) Co Overview
- Year Founded
-
2009
- Status
-
Public
- Employees
-
1,922
- Stock Symbol
-
02315
- Investments
-
4
- Share Price
-
$5.28
- (As of Friday Closing)
Biocytogen Pharmaceuticals (Beijing) Co General Information
Description
Biocytogen Pharmaceuticals (Beijing) Co Ltd is a biopharmaceutical and pre-clinical research services company. It has two Core Products, YH003 and YH001. YH003 is a recombinant humanized agonistic anti-Cluster of Differentiation 40 (CD40) Immunoglobulin G2 (IgG2) monoclonal antibody and YH001 is a recombinant humanized anti-CTLA-4, a protein receptor expressed constitutively on T cells that functions as an immune checkpoint and downregulates immune responses, Immunoglobulin G1 (IgG1) monoclonal antibody. YH003 is being developed for pancreatic ductal adenocarcinoma, melanoma, and other developed solid tumors. YH001 is being developed for hepatocellular carcinoma (HCC), non-small-cell lung carcinoma (NSCLC), and other solid tumors.
Contact Information
Website
www.biocytogen.comCorporate Office
- Number 12, Baoshen South Street
- Daxing District
- Beijing, 102629
- China
Corporate Office
- Number 12, Baoshen South Street
- Daxing District
- Beijing, 102629
- China
Biocytogen Pharmaceuticals (Beijing) Co Stock Performance
As of 13-Nov-2026, Biocytogen Pharmaceuticals (Beijing) Co’s stock price is $5.28. Its current market cap is $5.77B with 444M shares.
(As of Friday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $5.28 | $5.59 | $3.19 - $10.28 | $5.77B | 444M | 2.08M | $0.12 |
Biocytogen Pharmaceuticals (Beijing) Co Financials Summary
As of 30-Jun-2026, Biocytogen Pharmaceuticals (Beijing) Co has a trailing 12-month revenue of $243M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 7,698,439 | 4,358,965 | 458,038 | 602,858 |
| Revenue | 242,839 | 191,732 | 136,640 | 101,332 |
| EBITDA | 57,739 | 41,517 | (15,269) | |
| Net Income | 52,348 | 24,084 | 4,675 | (54,128) |
| Total Assets | 536,119 | 532,303 | 330,860 | 345,542 |
| Total Debt | 102,070 | 83,481 | 78,119 | 76,758 |
Biocytogen Pharmaceuticals (Beijing) Co Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
Biocytogen Pharmaceuticals (Beijing) Co Comparisons
Industry
Financing
Details
Biocytogen Pharmaceuticals (Beijing) Co Competitors (13)
One of Biocytogen Pharmaceuticals (Beijing) Co’s 13 competitors is Alnylam Pharmaceuticals, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Alnylam Pharmaceuticals | Formerly VC-backed | Cambridge, MA | ||||
| Crown Bioscience | Formerly VC-backed | San Diego, CA | ||||
| Metacrine | Formerly VC-backed | San Diego, CA | ||||
| 4D Molecular Therapeutics | Formerly VC-backed | Emeryville, CA | ||||
| Celprogen | Private Debt Financed | Torrance, CA |
Biocytogen Pharmaceuticals (Beijing) Co Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Biocytogen Pharmaceuticals (Beijing) Co Patents
Biocytogen Pharmaceuticals (Beijing) Co Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2021018198-A1 | Genetically modified non-human animal with human or chimeric il33 | Inactive | 29-Jul-2019 | ||
| WO-2020169022-A1 | Genetically modified non-human animals with humanized immunoglobulin locus | Inactive | 18-Feb-2019 | ||
| WO-2020147829-A1 | Humanized transgenic animal | Inactive | 17-Jan-2019 | ||
| WO-2020135518-A1 | Genetically modified non-human animal with human or chimeric il15 | Inactive | 25-Dec-2018 | ||
| WO-2020125763-A1 | Genetically modified non-human animal with human or chimeric lag3 | Inactive | 20-Dec-2018 | A01K67/0278 |
Biocytogen Pharmaceuticals (Beijing) Co Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Biocytogen Pharmaceuticals (Beijing) Co Investments & Acquisitions (4)
Biocytogen Pharmaceuticals (Beijing) Co’s most recent deal was a IPO with XtalPi Technology for . The deal was made on 13-Jun-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| XtalPi Technology | 13-Jun-2024 | IPO | Other Healthcare Technology Systems | ||
| Doma (Drug Discovery) | 31-May-2022 | Early Stage VC | Drug Discovery | ||
| Kactus | 28-Sep-2020 | Early Stage VC | Biotechnology | ||
| Eucure Biopharma | 24-Sep-2020 | Merger/Acquisition | Drug Discovery |
Biocytogen Pharmaceuticals (Beijing) Co ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Commercial Services
Industry
Rank
Percentile
Business Support Services
Subindustry
Rank
Percentile
Biocytogen Pharmaceuticals (Beijing) Co Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Eucure Biopharma | Beijing, China | 2016 |
Biocytogen Pharmaceuticals (Beijing) Co FAQs
-
When was Biocytogen Pharmaceuticals (Beijing) Co founded?
Biocytogen Pharmaceuticals (Beijing) Co was founded in 2009.
-
Where is Biocytogen Pharmaceuticals (Beijing) Co headquartered?
Biocytogen Pharmaceuticals (Beijing) Co is headquartered in Beijing, China.
-
What is the size of Biocytogen Pharmaceuticals (Beijing) Co?
Biocytogen Pharmaceuticals (Beijing) Co has 1,922 total employees.
-
What industry is Biocytogen Pharmaceuticals (Beijing) Co in?
Biocytogen Pharmaceuticals (Beijing) Co’s primary industry is Pharmaceuticals.
-
Is Biocytogen Pharmaceuticals (Beijing) Co a private or public company?
Biocytogen Pharmaceuticals (Beijing) Co is a Public company.
-
What is Biocytogen Pharmaceuticals (Beijing) Co’s stock symbol?
The ticker symbol for Biocytogen Pharmaceuticals (Beijing) Co is 02315.
-
What is the current stock price of Biocytogen Pharmaceuticals (Beijing) Co?
As of 13-Nov-2026 the stock price of Biocytogen Pharmaceuticals (Beijing) Co is $5.28.
-
What is the current market cap of Biocytogen Pharmaceuticals (Beijing) Co?
The current market capitalization of Biocytogen Pharmaceuticals (Beijing) Co is $5.77B.
-
What is Biocytogen Pharmaceuticals (Beijing) Co’s current revenue?
The trailing twelve month revenue for Biocytogen Pharmaceuticals (Beijing) Co is $243M.
-
Who are Biocytogen Pharmaceuticals (Beijing) Co’s competitors?
Alnylam Pharmaceuticals, Crown Bioscience, Metacrine, 4D Molecular Therapeutics, and Celprogen are some of the 13 competitors of Biocytogen Pharmaceuticals (Beijing) Co.
-
What is Biocytogen Pharmaceuticals (Beijing) Co’s annual earnings per share (EPS)?
Biocytogen Pharmaceuticals (Beijing) Co’s EPS for 12 months was $0.12.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
